Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

CCP TECHNOLOGIES LIMITED23/11/201604/06/2020
AGENIX LIMITED22/06/200123/11/2016

Shareholder links

Our website ranking of AGX: rating 4
(4 out of 5)



Advanced Share Registry Services
110 Stirling Hwy, Nedlands WA 6009
Tel : +61 8 9389 8033
Fax : +61 8 9262 3723
RegistryWebsite RegistryEmail

Company details

Address: Suite 202, 22 St Kilda Road St Kilda Victoria 3182
Tel:  +61 0467 559 037Fax: +61 3 8616 0382

Date first listed: 08/10/1987

Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Cardiovascular diagnostic products

News & Events

Expand this box to read and print

name changed to CCP Technologies Limited


The securities of Agenix Limited will be reinstated to official quotation as from the commencement of trading on Friday, 16 September 2016, following the Company's compliance with listing rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules.


The company advises that its application for readmission to the Official List of the ASX is currently being reviewed by the ASX. The final determination of whether or not to accept the application, is determined by the ASX.


we understand that on or about this date the company consolidated its shares 1 for 5


The company lodges its Preliminary Final Report.


The company is pleased to announce that the Prospectus Offer dated 29 June 2016, has been closed oversubscribed following strong support. The Prospectus Offer closed following the receipt of subscriptions to raise a total of $3,000,000 through the issue of 60,000,000 shares at $0.05 per share on a post consolidation basis. In accordance with the Prospectus and the approval granted by Shareholders at the Extraordinary General Meeting held on 29 June 2016, the oversubscription will in the first instance be applied to the subscription applications received from the Directors.


Under listing rule 17.6, any entity (if not already suspended) that had not paid its annual listing fees by close of business on Monday 22 August 2016 will have its securities suspended from official quotation before the commencement of trading on Tuesday 23 August 2016. The company has not paid its annual listing fees in respect of the year ending 30 June 2017 but the securities are already suspended from official quotation.


The company updates its consolidation.


Consolidation canceled due to submission of amended timetable.


Shareholders get 1 share for every 5 previously held.


Agenix Limited advises that pursuant to a resolution of the Board the timetable in respect of the Offer under the Prospectus lodged on 30 June 2016 has been extended. The extension arises from the lodgment of a supplementary prospectus dated 1 August 2016 and lodged with ASIC on that date.


The company releases a supplementary prospectus in relation to its Public Offer of up to 60,000,000 New Shares at an  Offer Price of $0.05 per New Share to raise $3 million and separate offer totalling 109,600,000 Acquisition Shares to CCP shareholders in connection with the acquisition CCP Holdings Pty Ltd and Cold Chain Partners Pty Limited. No funds will be raised from the Acquisition Offer.


The company lodges its quarterly report.


The securities of Agenix Limited (the "Company") will be suspended from quotation immediately following the receipt of shareholder approval for the Company to change its activities. In accordance with ASX's requirements for compliance with Chapter 11 of Listing Rules, the Company's securities will remain suspended until the Company has complied with Chapter 1 and 2 of Listing Rules.


Completion of Share Consolidation (for every 25 held previously, shareholders get 1)


we understand that on or about this date the company consolidated its shares 1 for 25


the Audited Annual Report for 30 June 2010 has been completed and has been lodged with the ASX on 31 August 2010 for announcement to the market


the suspension of trading in the securities of Agenix Limited (the "Company") will be lifted at 10:00 AM (A.E.S.T.) on Friday, 10 September 2010, following lodgement of the Company's Financial Report for the year ended 30 June 2010 and receipt of an announcement providing details of the Company's current financial and operational position


releases Preliminary Final Report and Financial Report For the Year Ended 30 June 2010


releases Executive Chairman`s Address to FY2009 AGM


Tang Wen Seng buys 20m Agenix shares


the Agenix Wholly Foreign Owned Enterprise: Agenix Biopharmaceutical (Shanghai) Co., Ltd (the Agenix WFOE) received in cleared funds the sum of RMB 2,800,000 (approximately AUD$ 477,000) in relation to the failed 2007 transaction


the Board anticipates that holding of the Annual General Meeting and a demonstrated adherence to ASX Listing Rules will enable shares in the company to resume trading on the ASX also in the third quarter of 2010. The Board cautions that the estimated timing of trading in its shares is indicative only and is subject to uncertainties outside of the control of the company, so undue reliance should not be placed on the indicative timing of its aims


releases various financial reports - the last (to 30 December 2010) shows net tangible asset backing per ordinary share of one fifth of a cent - the balance sheet shows that liabilities exceed assts by $929,000 and cash flows at operating level were a negative $1.2m for the six months - the auditors say the accounts "indicate the existence of a material uncertainty which may cast significant doubt as to the consolidated entity's ability to continue as going concern"


reports that recovery efforts in relation to the Chinese bio-pharmaceutical investments continue to produce results. In February 2010, the Agenix Wholly Foreign Owned Enterprise: Agenix Biopharmaceutical (Shanghai) Co., Ltd (the Agenix WFOE) collected the sum of RMB3,500,000 (approximately AUD$ 560,000) in relation to the failed 2007 transaction.


company provides a 14 page update on operations


company reports that between January 2006 and December 2007 the former Chief Executive Officer, Chief Financial Officer and Company Secretary of the company during the period May 2003 to May 2008, Mr Neil Leggett authorised the fraudulent transfer of $5.562 million to a company under the control of the Leggett family. It was also identified that part of that had been remitted back to the Company during this time leaving a net defalcation of $3.79 million. Subsequent to the discovery of the fraud, a civil action was commenced by Agenix in the Victorian Supreme Court against Neil Leggett, his wife and a controlled company and, pursuant to that proceeding, the assets of the former CEO, his wife and the controlled company were frozen while further investigations were conducted by Agenix with a view to recover the misappropriated funds. Mr Leggett and his wife entered into voluntarily bankruptcy on 11 September 2008 and they voluntarily appointed liquidators over companies under their control. The Trustee in Bankruptcy is presently pursuing repayment of funds from the trustee of their superannuation fund in the Federal Magistrates Court, listed for trial in July 2010


has secured a $5 million equity-drawn down funding facility with investment bank Fortrend Securities Pty Ltd, which involves Agenix placing shares with Fortrend over the next three years - Fortrend has agreed to provide up to $5 million to Agenix to be drawn down, at any time over the next three years, at the discretion of Agenix, by the issue of new shares to Fortrend, subject to the lifting of voluntary suspension from trading of its shares on the ASX. Agenix has agreed to issue a prospectus and is obliged to make three draw downs in the first 12 months should voluntary suspension from trading of its shares on the ASX be lifted, but is otherwise under no obligation to issue shares


recovery efforts in relation to the Chinese bio-pharmaceutical investments continue to produce results - the company collected app $A237,000 in December 2009, in addition to the $A237,000 collected in November 2009.


the proposed variation to the settlement with the Chinese company has not been executed and the company has asserted its right to revert to and enforce the original purchase documentation


$600,000 raised by way of convertible notes in October 2008 have now converted to 47.5 million shares - that values the shares at about 1.25 cents


company is agreeing in principle to vary the settlement with the Chinese company


releases FY2008 AGM Chairman`s Address and Results of FY2008 AGM


the 2008 AGM is to be held on 31 October 2009


annual report to 30 June 2008 is finally released - yes that is 2008 not 2009 - predictably it is awash with red ink - $23m loss, $15m cash deficit at operating level and virtually zilch in net assets after elimination of intangibles


company says it has entered into a Deed of Variation with Noteholders that defers shareholder approval of the private placement to 1 December 2009 - and no surprises, the company is still working on last year's financial statements


ceo Stephen Phua's contract is not to be renewed


company reports it has received a further instalment of RMB 500,000


company says it has raised $1m from the placement of unlisted convertible notes to two sophisticated investors - notes that will convert to shares at half a cent a share - it now expects to hold its 2008 AGM by 30 September 2009 (about the time most companies are holding their 2009 AGMs!!)


company reports it has received a further instalment of RMB 500,000


company provides an update


Agenix apologises for an error in its release yesterday when chairman Nicholas Weston stated "in particular, we note that the current price for those shares on the ASX is $0.17" - "the correct value is in fact $0.017 (i.e. 1.7 cents) being the last market sale of Agenix ordinary shares prior to voluntary suspension in August 2008" - we note that this apology has not been posted to Agenix's website (at least not by 4 June)


company issues a warning to shareholders of unsolicited offers for its shares - Agenix has not only made unsubstantiated, misleading and erroneous allegations about deListed in their release of today, it has ignored our request that the facts be provided to shareholders


advises that the commercial terms to settle the dispute over its PRC investments have been agreed


the company provides another update on Company Operations - now says it will have financial reports (to 30 June 2008) ready for an AGM by 30 June 2009 - better late than never, but by then a further 12 months will have elapsed and financial reports that historical are close to meaningless


board provides an update on Company Operations


Agenix announces that its lead product ThromboView has met the criteria to progress to its final development


advises that the Preliminary Settlement Deed (PSD) resolving the acquisition of the Chinese bio-pharmaceutical investments has lapsed - due to this change Agenix is working to settle the FSD prior to the Chinese New Year so that the second and third instalments due under the lapsed PSD (5% by the 10 January 2009 and 30% by 31 January 2009) may be paid in one instalment of 35% due by 31 January 2009


company says it is in talks with parties in China to resolve the Chinese acquisition, complete the annual report and resume trading on ASX - one or two months may be needed


company resolves to raise $600k through a note issue and $200k via a private placement of shares


the litigation referred to below returns to the court on 20 September 2008 for directions - the remaining defendants are Neil Leggett and Julie Leggett - Neil Leggett was a former CEO, CFO and Company Secretary of the company - the company claims that improper transactions of $3.865m occurred during 2006, 2007 and 2008


litigation is underway against a former director of Agenix - the proceedings have been stayed because a related trustee company has been placed in creditors voluntary liquidation


securities suspended pending release of an announcement


name changed from Biotech International Limited



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    30/09/2016Craig Chapman1,112,218$0.050$55,581
    20/09/2016Adam Gallagher1,500,000$0.053$79,643
    12/09/2015Chris McNamara-154,616$0.010$1,576

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Leath NicholsonNon Exec Chairman, Independent Director14/10/2016
    Garry TaylorCFO, Company Secretary31/03/2011
    Anoosh ManzooriIndependent Director14/10/2016
    Anthony LeeNon Exec Director27/08/2007
    Chris McNamaraNon Exec Director01/02/2008
    Adam GallagherNon Exec Director01/06/2015
    Michael White Director07/09/2016
    Anthony RowleyDirector07/09/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Craig ChapmanNon Exec Director21/05/201318/11/2016
    Nicholas WestonExecutive Chairman, CEO22/08/200801/06/2015

    Date of first appointment, title may have changed.